| Julie Staub, CRNP | |
|
361 Alexander Spring Rd, Carlisle, PA 17015-6940 | |
| (717) 960-1687 | |
| Not Available |
| Full Name | Julie Staub |
|---|---|
| Gender | Female |
| Speciality | Pediatrics - Neonatal-perinatal Medicine |
| Location | 361 Alexander Spring Rd, Carlisle, Pennsylvania |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1780182147 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2080N0001X | Pediatrics - Neonatal-perinatal Medicine | SP018139 (Pennsylvania) | Primary |
| Entity Name | Wellspan Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750480299 PECOS PAC ID: 1951213115 Enrollment ID: O20040220000815 |
News Archive
Scientific advances at The Scripps Research Institute have led to a new drug Surfaxin (lucinactant), approved today by the U.S. Food and Drug Administration (FDA) to treat infant respiratory distress syndrome.
Nanobiotix, a company developing novel cancer nanotherapeutics, announced today that its lead compound NBTXR3 has received the formal authorization from the French Medicine Agency, AFSSAPS, to start the first clinical trial.
MSD, known as Merck in the United States and Canada, announced final results from a Phase III, open-label study designed to compare the impact of two anaemia management strategies on sustained virologic response (SVR) in patients with chronic hepatitis C virus (HCV) genotype 1 infection treated with VICTRELIS(boceprevir) in combination with PEGINTRON and ribavirin.
Studies conducted at the Comprehensive Cancer Center at MedUni Vienna and Vienna General Hospital show that the drugs ibrutinib and idelalisib used in the targeted treatment of chronic lymphatic leukaemia can significantly prolong the survival time of high-risk patients.
A high proportion of multidrug-resistant tuberculosis cases can be cured in conflict-affected communities with molecular diagnostics, shorter treatment periods and socioeconomic incentives, according to the results of a large, long-term study in the Democratic Republic of Congo led by the University of Pittsburgh Graduate School of Public Health and Stellenbosch University in South Africa, in collaboration with the DRC National Tuberculosis Program.
› Verified 2 days ago
| Entity Name | Pinnacle Health Medical Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932143427 PECOS PAC ID: 7618960493 Enrollment ID: O20040407000180 |
News Archive
Scientific advances at The Scripps Research Institute have led to a new drug Surfaxin (lucinactant), approved today by the U.S. Food and Drug Administration (FDA) to treat infant respiratory distress syndrome.
Nanobiotix, a company developing novel cancer nanotherapeutics, announced today that its lead compound NBTXR3 has received the formal authorization from the French Medicine Agency, AFSSAPS, to start the first clinical trial.
MSD, known as Merck in the United States and Canada, announced final results from a Phase III, open-label study designed to compare the impact of two anaemia management strategies on sustained virologic response (SVR) in patients with chronic hepatitis C virus (HCV) genotype 1 infection treated with VICTRELIS(boceprevir) in combination with PEGINTRON and ribavirin.
Studies conducted at the Comprehensive Cancer Center at MedUni Vienna and Vienna General Hospital show that the drugs ibrutinib and idelalisib used in the targeted treatment of chronic lymphatic leukaemia can significantly prolong the survival time of high-risk patients.
A high proportion of multidrug-resistant tuberculosis cases can be cured in conflict-affected communities with molecular diagnostics, shorter treatment periods and socioeconomic incentives, according to the results of a large, long-term study in the Democratic Republic of Congo led by the University of Pittsburgh Graduate School of Public Health and Stellenbosch University in South Africa, in collaboration with the DRC National Tuberculosis Program.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Julie Staub, CRNP 361 Alexander Spring Rd, Carlisle, PA 17015-6940 Ph: (717) 960-1687 | Julie Staub, CRNP 361 Alexander Spring Rd, Carlisle, PA 17015-6940 Ph: (717) 960-1687 |
News Archive
Scientific advances at The Scripps Research Institute have led to a new drug Surfaxin (lucinactant), approved today by the U.S. Food and Drug Administration (FDA) to treat infant respiratory distress syndrome.
Nanobiotix, a company developing novel cancer nanotherapeutics, announced today that its lead compound NBTXR3 has received the formal authorization from the French Medicine Agency, AFSSAPS, to start the first clinical trial.
MSD, known as Merck in the United States and Canada, announced final results from a Phase III, open-label study designed to compare the impact of two anaemia management strategies on sustained virologic response (SVR) in patients with chronic hepatitis C virus (HCV) genotype 1 infection treated with VICTRELIS(boceprevir) in combination with PEGINTRON and ribavirin.
Studies conducted at the Comprehensive Cancer Center at MedUni Vienna and Vienna General Hospital show that the drugs ibrutinib and idelalisib used in the targeted treatment of chronic lymphatic leukaemia can significantly prolong the survival time of high-risk patients.
A high proportion of multidrug-resistant tuberculosis cases can be cured in conflict-affected communities with molecular diagnostics, shorter treatment periods and socioeconomic incentives, according to the results of a large, long-term study in the Democratic Republic of Congo led by the University of Pittsburgh Graduate School of Public Health and Stellenbosch University in South Africa, in collaboration with the DRC National Tuberculosis Program.
› Verified 2 days ago
Dr. Deborah Raubenstine, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 804 Belvedere St, Carlisle, PA 17013 Phone: 717-243-1653 Fax: 717-243-6708 | |
Mr. Eliseo Rosario Jr., M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 804 Belvedere St, Carlisle, PA 17013 Phone: 717-243-1653 Fax: 717-243-6708 | |
Mrs. Shauntara Ann Angelo, CRNP Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 361 Alexander Spring Rd, Carlisle, PA 17015 Phone: 717-960-3414 | |
Dr. Stephanie Renee Waters, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 804 Belvedere St, Carlisle, PA 17013 Phone: 717-243-1653 Fax: 717-243-6708 | |
Dr. Stephen J Krebs, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 804 Belvedere St, Carlisle, PA 17013 Phone: 717-246-1653 Fax: 717-243-6708 | |
Dr. Jay Lynn Hoffman, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 804 Belvedere St, Carlisle, PA 17013 Phone: 717-243-1653 Fax: 717-243-6708 | |
Mrs. Elena Man, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 804 Belvedere St, Carlisle, PA 17013 Phone: 717-243-1653 Fax: 717-243-6708 |